前收市價 | 0.0500 |
開市 | 0.0500 |
買盤 | 0.0000 |
賣出價 | 0.7500 |
拍板 | 30.00 |
到期日 | 2024-10-18 |
今日波幅 | 0.0300 - 0.0500 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 5 |
Gilead Sciences and Nuvalent are in the spotlight following positive updates on key candidates.
ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.
Monday, the FDA lifted the partial clinical hold on studies of Zentalis Pharmaceuticals, Inc.’s (NASDAQ:ZNTL) azenosertib, the company’s novel, selective, and orally bioavailable inhibitor of WEE1. The FDA has cleared the company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan. Zentalis will be working with clinical trial investigators to resume study activities across the azenosertib development program as quickly as possible. Al